|Articles|November 1, 2002

Is the cesarean rate too high? Yes.

Yes. It could be lower but it is difficult to know whether it really should be lower.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!

Related Content

High costs and transfusions linked to acute heavy menstrual bleeding

ByCeleste Krewson, Assistant Editor

December 13th 2025

Oral zoliflodacin offers new option for gonorrhea treatment, says Edward Hook, MD

Edward Hook, MD, discusses FDA approval of oral zoliflodacin for uncomplicated gonorrhea

ByEdward Hook, MD

December 12th 2025

FDA approves Nuzolvence (zoliflodacin) for uncomplicated gonorrhea

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea

ByMorgan Ebert, Managing Editor

December 12th 2025

Contemporary OB/GYN week in review: HPV vaccine, postpartum depression, and more

ByCeleste Krewson, Assistant Editor

December 12th 2025

George L. Maxwell, MD, discusses phase 3 SUNFLOWER trial to evaluate Mirena for nonatypical endometrial hyperplasia

ByGeorge L. Maxwell, MD

December 12th 2025

Latest CME

Multimedia

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Rachel N. Grisham, MD; Domenica Lorusso, MD, PhD

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN

Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD

Video

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Is the cesarean rate too high? Yes.

Newsletter

Related Content

High costs and transfusions linked to acute heavy menstrual bleeding

Edward Hook, MD, discusses FDA approval of oral zoliflodacin for uncomplicated gonorrhea

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea

Contemporary OB/GYN week in review: HPV vaccine, postpartum depression, and more

George L. Maxwell, MD, discusses phase 3 SUNFLOWER trial to evaluate Mirena for nonatypical endometrial hyperplasia

Latest CME

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Trending on Contemporary OB/GYN

DARE to PLAY sildenafil cream becomes commercially available for women in select states

Edward Hook, MD, discusses FDA approval of oral zoliflodacin for uncomplicated gonorrhea

High costs and transfusions linked to acute heavy menstrual bleeding

FDA approves zoliflodacin (Nuzolvence) for uncomplicated gonorrhea

Contemporary OB/GYN week in review: HPV vaccine, postpartum depression, and more